DIAアカウントをお持ちの場合、サインインしてください。

サインイン

ユーザーIDをお忘れですか? or パスワードをお忘れですか?

The Board of Directors collaborates to provide strategic clarity, direction, and policy objectives for DIA. The Board of Directors and its Standing Committees ensure DIA meets the requirements of our members in the content of our programs, research, and financial decisions.

Board membership is voluntary, and DIA does not compensate Directors or members of Advisory Councils for their contributions.

Kihito Takahashi

Chair of DIA Board

Chair of Executive Committee

  
Dr. Takahashi is currently Partner at Mirasense Partners. He graduated from Hokkaido University School of Medicine and receiving his PhD in Medical Science in 1986. He served as VP, Merck Research Laboratories from 2003 to 2008. He joined LOTUS Pharmaceutical Co. Ltd, a bio-venture company in 2009, and served as a President & CEO before joining GSK, where he served as VP and Director of Japan Development until 2019. After retiring GSK, he served as Director and COO at BONAC Corporation, a bio-venture company, and then joined Mirasense Partners in 2020. He has been actively involved in industry activities including DIA, IFAPP, and EFPIA since he joined pharmaceutical industry. He is currently serving as a Councilor of JAPhMed.

Rachel Zhang

Chair-Elect

  
Rachel has over two decades of healthcare consulting and life science management experiences. Formerly a partner in McKinsey & Company’s New York Office, Rachel oversaw the design and delivery of corporate and R&D transformation programs, working with leading pharmaceutical companies as well as global health non-profit organizations. In 2016 she founded New Path Global LLC, to strengthen collaboration across academia, industry, and funders, towards long-term patient and society benefits. Rachel started her career as a drug discovery biochemist with Merck Research Laboratories in West Point, Pennsylvania. She also obtained an MBA from The Wharton School

Michael Rosenblatt

Immediate Past Chair

Chair of Governance Committee

  
Michael Rosenblatt, MD, Senior Partner at Flagship Pioneering, has advanced academic and biopharmaceutical research and development throughout his career. He was previously Chief Medical Officer for Merck, after serving as Dean of Tufts Medical School. Formerly, he was Ebert Professor of Molecular Medicine and Minot Professor at Harvard. He served as President of Beth Israel Deaconess Medical Center and as Director of the Harvard-MIT Division of Health Sciences & Technology. He is on the board of several life sciences companies, and on the Harvard Medical School Board of Fellows and research advisory committees of the Massachusetts General, Brigham and Women’s, and Boston Children’s Hospitals. He earned his MD from Harvard Medical School.

Tatyana Kosheleva

Secretary/Treasurer

Chair of Finance Committee

  
Tatyana Kosheleva, CPA, is currently CFO at Amring Pharmaceuticals Inc. where she is a member of the Executive Board responsible for all aspects of the firm's financial operations. Tatyana has over 20 years of diverse Finance experience ranging from start-ups to Fortune 50 public companies in the life sciences and technology industries across four countries. Tatyana earned her MBA degree in International Management from Thunderbird School of Global Management, a part of the Arizona State University.

Marwan Fathallah

President & Chief Executive Officer

  
Prior to joining DIA in 2023, Fathallah was the Operating Officer and EVP at Ortho Clinical Diagnostics, accountable for Operations, Post Market Product Science and Engineering, Regulatory, Quality, Medical, Clinical, Scientific Affairs, and Process Excellence. Before joining Ortho, he held Executive and Senior Leadership roles in Research and Development, Operations, and Regulatory Medical and Clinical Affairs at Avantor, Danaher, Pfizer, Hospira, and Abbott Laboratories. Fathallah holds a Master’s and Bachelor of Science degrees in Mechanical Engineering from the Univ. of Wisconsin-Madison and an MBA from the Kellogg School of Management at Northwestern University.

Junaid Bajwa

Director

  
Junaid is the Chief Medical Scientist at Microsoft Research and a practicing physician in the UK’s National Health Service. Junaid has worked across primary care, secondary care, and public health settings in addition to acting as a payer, and policymaker within the UK, where he specialized in informatics, digital transformation, and leadership. He has consulted for health care systems across the US, Europe, Australia, the Middle East, Singapore, and Europe. Academically, he is a Clinical Associate Professor at UCL (University College London), and Visiting Scientist at the Harvard School of Public Health.

Peter Honig

Director

  
Dr. Honig is former SVP and Head of Global Regulatory Affairs and Group Head of Development for China and Japan, overseeing regulatory effectiveness, quality control and compliance at Pfizer. Prior to joining Pfizer, he held senior leadership positions at AstraZeneca, Merck Research Laboratories and the FDA, which includes being the first Director of the Office of Drug Safety in the FDA’s Center for Drug Evaluation and Research (CDER). In addition to his industry and FDA experience, Dr. Honig was the PhRMA representative to the ICH Steering Committee from 2002 to 2021 and is a past President of the American Society for Clinical Pharmacology and Therapeutics (ASCPT). Dr. Honig received his BA, MD, and MPH from Columbia University.

Zili Li

Director

  
Zili oversees all R&D activities within Asia Pacific, leading over 1,400 science professionals dedicated to delivering transformational healthcare innovation across the region. Zili joined Janssen in June 2019 from the FDA where he served as Associate Director for Global Affairs at the Office of Generic Drugs. There he contributed significantly to the expansion of the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) to the field of generic drugs, playing a critical role in China’s National Medical Products Administration’s membership in ICH in 2017. Zili is a graduate of Peking Union Medical College and completed his residency training at Johns Hopkins in 2000.

Jason Monteleone

Director

Chair of Audit Committee

  
Jason joined Ancillare as President with over 25 years of experience in the healthcare, medical device, and life sciences industries. He most recently served as Chief Business and Strategy Officer at dMed-Clinipace, a global mid-sized Contract Research Organization (CRO), and Chief Executive Officer at Clinipace prior to its 2021 merger with dMed. In prior years, Jason founded Pivotal Financial Consulting, a consultancy where he advised investors and companies in the clinical research sector, focused on acquisitions, growth and innovation. Jason was also Chief Financial Officer and Executive Vice President for Theorem Clinical Research, a global mid-sized Contract Research Organization acquired by Chiltern International in 2015.

David Mukanga

Director

  
Dr. David Mukanga is Deputy Director Africa Regulatory Systems at the Bill & Melinda Gates Foundation, where he leads the foundation’s Africa regulatory systems optimization portfolio, and the linkage between regulatory systems and health care services. In this role, David supports the development of harmonized, transparent, and predictable regulatory systems covering the lifecycle of medical products in Africa across the national, regional, and continental levels of the ecosystem. His work also involves support for regulatory emergency preparedness. In this role he works side by side with partners on the African continent to facilitate development of new medical products, as well as patient access to quality essential medicines.

Chockalingam Palaniappan

Director

  
Member of the DIA Board of Directors and also serves as the Co-chair for the DIA Science Policy Advisory Committee. He is an accomplished global life sciences innovation executive with more than 20 years of leadership experience across three multinational corporations, GE Healthcare, Life Technologies, and Terumo BCT, delivering over $500M in career revenue. Palani has a considerable track record in breadth and depth from a medical product development standpoint, and has worked in the areas of drugs, devices, and diagnostics. Palani has a Ph.D. in the field of biological sciences from Northern Illinois University, followed on by a post-doctoral fellowship at the University of Rochester in HIV biology.

Peter Ronco

Director

  
Peter is an accomplished drug developer and innovative senior pharmaceutical executive who advises boards, private equity investors, and leaders across the pharmaceutical and biotech industry. He has extensive global experience across a broad range of therapeutic areas, including oncology, immunology, neuroscience, vaccines, anti-infectives, cardiovascular and retinal gene therapy - from First in Human to Medical Affairs. Prior to joining Janssen in 2017, Peter was the SVP of Global Clinical Operations at BMS where he had spent 14 years holding positions of increasing leadership scope in Medical Affairs, Regulatory Operations and R&D Operations. He also served on the TransCelerate Biopharmaceutical Board of Directors.

Peter Sorger

Director

  
Peter Sorger is the Otto Krayer Professor of Systems Pharmacology at Harvard Medical School. He received his AB from Harvard College and PhD from Trinity College, Cambridge University U.K., working under the supervision of Hugh Pelham. He trained as a postdoctoral fellow at the University of California, San Francisco with Harold Varmus and Andrew Murray. Prior to coming to HMS Peter served as a Professor of Biology and Biological Engineering at MIT. Sorger was cofounder of Merrimack Pharmaceuticals and Glencoe Software and is an advisor to multiple public and private companies and research institutes in the US, Europe and Japan.

Craig Carra

Strategic Advisor to the Board of Directors

  
Craig is an executive leader with a strong, diverse background in finance, operations, and business development. 20 years of experience with both private and public emerging growth, life science companies, including 8+ years serving as CFO. Demonstrated success and significant business performance improvements across multiple corporate functions to drive financial performance through organic revenue growth, acquisitions, and operational efficiencies. Craig holds an active CPA license, has an undergraduate degree in Accounting from Saint Joseph’s University, and an Executive MBA degree from Villanova University.

Frank N. Jiang

Strategic Advisor to the Board of Directors

  
Dr. Jiang has over 30 years of experience in management of medical practice and pharmaceutical industry. Dr. Jiang is the Chief Strategy Officer and a Board Director at Hengrui (a global top 50 pharma), where he oversees corporate strategy, clinical development, and business development. Prior to Hengrui, Dr. Jiang served as the founding CEO and Chairman of the Board at CStone Pharmaceuticals, a leading biotech in China where Dr. Jiang led the team to build its pipeline from zero to 16 assets, including 4 marketed products with a total of 10 approved indications. Prior to CStone, Dr. Jiang was the Head of Asia Pacific R&D (including Japan) for Sanofi.

Kim Quaintance-Lunn

Strategic Advisor to the Board of Directors

  
Kim Quaintance-Lunn is the Vice President, Regulatory Affairs Americas and a Distinguished Science Fellow at Bayer, a Director at Large for the FDA Alumni Association, and Chair of DIA's Americas Regional Advisory Council. At Bayer, Kim serves in a leadership capacity for US Regulatory Affairs, functions as the expert on FDA standards, regulations, legislative actions and processes, and is the lead for several patient focused initiatives. Kim joined Bayer in February 2014 as Head of US Regulatory Policy. Kim previously served as the Senior Director, Global Regulatory Policy and Intelligence at Eisai, Associate Director for Regulatory Affairs in CDER’s Office of New Drugs, and began her career as a research scientist at Pfizer.

Xiaojun (Wendy) Yan

Strategic Advisor to the Board of Directors

  
Wendy is a pharmacist by training, having graduated from Beijing Traditional Chinese Medicine University (China) and received an MBA from Staffordshire University (UK).  She began her career in Beijing Drug Control Institute, subordinate organization of China NMPA in 1988. Since 1996, she had held multiple leading Regulatory Affairs positions at several multinational pharmaceutical companies for 18 years. Wendy joined BeiGene as the Senior Vice President, Global Head of Regulatory Affairs in August 2014. She was appointed as Senior Vice President, Chief Regulatory Officer since 2021.  Wendy has been former Member of DIA Advisory Council of China (ACC). Wendy is Professor of YEEHONG Business School. She is DIA board members as observer.

最新情報や機会を逃さないで

DIAのメールを購読すれば、常に最新の業界情報やイベント情報を得ることができます。